Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Teeth Whitening

California Medical Association Applauds Obama's Push For Health Care Reform
The California Medical Association called on President Obama today to fix the flaws with Medi-Cal and Medicare, the government"s two biggest health care programs, as part of efforts to reform health care and extend coverage to those who are uninsured.
generic viagra online
Young Adults Face Tough Time Getting Insurance
Young adults are facing tough times with limited job prospects and no health insurance. The Associated Press reports on recent college graduate Emily Weinstein as being representative of the many young uninsured Americans: "Like millions of other uninsured adults in their 20s, Weinstein is watching Congress as it advances legislation to overhaul health care. The recession has deepened young adults" career struggles. It has also sharpened their interest in health insurance. Already the least likely of any age group to have coverage, adults in their 20s face brutal job searches and more time uninsured because of the recession. Nearly 30 percent, 13.2 million, were uninsured in 2007, according to the Commonwealth Fund, a New York-based research center. Many young adults work entry-level jobs without insurance and, despite new laws in some states, they"re eventually too old to stay on their parents" policies."
News of the day
African-American Women With Advanced Breast Cancer Often Forego Vital Treatment
A new study finds that nearly one in four African American women with late stage breast cancer refused chemotherapy and radiation therapy, potentially life saving therapies. Published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that more efforts are needed to ensure that all women with breast cancer receive appropriate care.
Oncology

SRI International To Screen Drugs That Fight 2009 H1N1 Influenza A

SRI International, an independent, nonprofit research and development organization, announced today that it will screen a library of well-characterized drugs against the 2009 H1N1 influenza A virus, previously known as "swine flu." The work will be performed under a re contract from the Division of Microbiology and Infectious Diseases (DMID) in the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. There is currently only one class of antiviral drugs, the neuraminidase inhibitors, available to treat this H1N1 infection. Identifying drugs from other chemical and mechanistic classes could provide more effective alternatives to current therapies and make it easier to provide sufficient quantities of drugs to a broad population, should the need arise. The development of new treatments may be expedited by screening drugs that have already well-characterized safety and toxicity profiles. "SRI has expertise in screening new and approved drugs, including the development of novel uses for antibiotics and screening a library of licensed drugs to find compounds that show efficacy against biothreat agents. SRI appreciates the opportunity to apply its knowledge and skills to screening drugs against H1N1 flu and contributing to the overall understanding of the virus," said Amy Shurtleff, Ph.D., a senior virologist in SRI International"s Biosciences Division, who will lead this screening program. Although the number of new 2009 H1N1 influenza A virus cases appears to be slowing worldwide, viruses are unpredictable. In particular, it is not known how this new virus will behave when the seasonal flu season returns this fall and in subsequent years. Scientists are looking at the Southern Hemisphere now, where the flu season will begin soon, for any signs of changes in the H1N1 virus and how humans respond to the infection. SRI has a long and successful history of drug discovery and development, which includes both screening of licensed drugs and finding and studying new chemical and biological therapeutics and vaccines. The virus will be handled in compliance with all guidelines prescribed by the Centers for Disease Control and Prevention (CDC) for handling this strain of influenza. SRI researchers will culture cell lines and study H1N1 virus growth under well-controlled conditions. Next, they will begin testing the first round of drugs. Assuming that some drugs show worthwhile efficacy and potency, SRI will help develop a plan for preclinical and clinical evaluation and regulatory approval. SRI International *See our Map Of H1N1 Outbreaks *See our Mexico Swine Flu Blog


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009